NAD alerts FDA, FTC to SlimForce 7 ad
This article was originally published in The Tan Sheet
Executive Summary
After failing to reach Toronto-based SlimForce 7, which markets a weight-loss product as a supplement under the same name, the Council of Better Business Bureaus unit refers the firm to FDA, the Federal Trade Commission and the Competition Bureau of Canada. NAD said Aug. 10 that a magazine ad claims SlimForce 7 "is a treatment aimed at all those who can't lose weight," enables loss of 11 pounds in one week and modifies the body's metabolism. The claims qualify as "too good to be true" under FTC's reference guide for bogus weight-loss claims (1"The Tan Sheet" Dec. 15, 2003). NAD said SlimForce 7 did not respond to multiple communication attempts
You may also be interested in...
NAD reviews weight-loss supplement
Artis Marketing says it will discontinue and modify advertising claims for its SlimForce7 weight-loss product following a recommendation by the National Advertising Division and referral to the Federal Trade Commission. The division of the Council of Better Business Bureaus found insufficient evidence to support the claim the product is a "treatment aimed at all those who can't seem to lose all the weight they want to lose," among other claims. NAD recommended the Toronto-based company discontinue testimonials and claims suggesting the product, made of six fruits and one algae, will result in weight loss regardless of diet and exercise. NAD's review of SlimForce7 follows a previous attempt to review claims for the product, after which the watchdog was unable to contact the advertiser and referred it to FTC, FDA and relevant Canadian agencies (1"The Tan Sheet" Aug. 17, 2009, In Brief). Subsequently, Artis agreed to participate in the review process, noting it permanently discontinued the original ads and modified many claims at issue. However, NAD found many of the modified claims presented similar concerns
Slap On The Wrist? FTC Puts Out Media Guidance On Weight Loss Ad Claims
A series of actions unveiled by the Federal Trade Commission to combat false advertising claims for weight loss products includes a set of media guidelines to help prevent dissemination of deceptive ads
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.